| HS Code | 583045 |
| Product | Trometamol Prostaglandin F2α Veterinary Grade API |
| Activeingredient | Dinoprost tromethamine (PGF2α tromethamine) |
| Chemicalname | Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9α,11α,13E,15S)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) |
| Casnumber | 38562-01-5 |
| Molecularformula | C24H45NO8 |
| Molecularweight | 475.62 g/mol |
| Appearance | White to off-white crystalline powder |
| Solubility | Freely soluble in water; soluble in methanol and ethanol; sparingly soluble in acetone |
| Meltingpoint | Approximately 100°C with decomposition |
| Storageconditions | Store at -20°C, protected from light and moisture, in airtight containers |
| Stability | Stable when stored under recommended conditions; avoid repeated freeze-thaw cycles |
| Mechanismofaction | Causes luteolysis by regression of the corpus luteum, leading to decreased progesterone and induction of estrus or parturition |
| Veterinaryindications | Estrus synchronization, luteolysis, induction of abortion, induction of parturition, and treatment of certain reproductive disorders such as pyometra and endometritis |
| Targetspecies | Cattle, horses, pigs, sheep, goats, dogs, and other veterinary species as directed |
| Routeofadministration | Intramuscular, subcutaneous, or as incorporated into the specified veterinary finished dosage forms |
| Dosageforms | Tablets, injections, capsules, powders, granules, premix, and solutions |
| Grade | Veterinary grade active pharmaceutical ingredient (API) |
As an accredited Trometamol Prostaglandin F₂α Injection Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sealed, light-protected containers with tamper-evident closures. Supplied as 1 kg veterinary-grade API for pharmaceutical formulations. |
| Container Loading (20′ FCL) | 20′ FCL container loading of Trometamol Prostaglandin F₂α Injection Veterinary Grade API, suitable for tablets, injections, capsules, powders, granules, premix, and solutions. |
| Shipping | This product requires strict cold-chain shipping (2–8°C) to maintain potency and stability. It must be packaged in temperature-controlled, insulated containers with gel packs and data loggers. Shipments are handled as hazardous pharmaceuticals, ensuring regulatory compliance for veterinary API transport. Use expedited couriers to minimize transit time and prevent temperature excursions. |
| Storage | Store Trometamol Prostaglandin F₂α Veterinary Grade API in a tightly sealed, light-resistant container in a cool, dry place. Recommended storage at 2–8°C under refrigerated conditions. Protect from moisture, heat, and direct sunlight. Avoid freezing. Ensure stable humidity and adequate ventilation. Keep away from incompatible substances. Maintain cold-chain integrity throughout handling and transport to preserve potency and purity. |
| Shelf Life | Shelf life is typically 24 months from manufacture when stored in original tightly sealed containers under recommended cool, dry conditions. |
In commercial feedlot reproductive protocols, dinoprost tromethamine injectable solution is formulated at 5 mg/mL dinoprost expressed as the tromethamine salt. The salt-to-free-acid conversion factor of 1.34 requires 6.7 mg/mL dinoprost tromethamine to deliver 5.0 mg/mL dinoprost. The addition ratio for a 1,000 L batch therefore begins with 6.70 kg API, corrected for the certified water content and residual solvent result. The registered indication under 21 CFR 522.690 covers estrus synchronization, unobserved estrus, pyometra, and abortion in feedlot heifers; each dosing event in cattle is 25 mg dinoprost, delivered as 5 mL of the 5 mg/mL solution. Multidose containers require an antimicrobial preservative, and the selected preservative must meet the antimicrobial effectiveness acceptance criteria of USP <51> or Ph. Eur. 5.1.3. Because the product is a parenteral solution, the finished batch is also subject to USP <1>, USP <71>, USP <85>, USP <788>, and USP <790>.
Compounding at production scale uses a 316L stainless steel jacketed vessel with bottom-mounted low-shear impeller. Water for injection is charged and sparged with nitrogen until dissolved oxygen falls below the validated in-process limit; an upper limit of ≤0.5 mg/L is often used to limit oxidation of the prostaglandin triol structure. API is added under nitrogen overlay at 20–25°C, and dissolution proceeds without heating because aqueous PGF₂α tromethamine is thermolabile. Sodium chloride is added to achieve 260–330 mOsm/kg by USP <785>. pH adjustment is performed with dilute tromethamine or hydrochloric acid; the target range is validated by stress-cycling between pH 6.8 and pH 7.4. High-shear rotor-stator mixing is avoided at this stage because air entrainment accelerates peroxide-mediated degradation and creates foam that complicates subsequent sterile filtration. After pH and osmolality adjustment, the bulk solution is held under positive nitrogen pressure and transferred to the filtration suite through closed sanitary piping.
The sterile filtration train uses a 0.45 µm bioburden-reduction prefilter followed by a 0.22 µm sterilizing-grade membrane, typically polyvinylidene fluoride or polyethersulfone. Filter membranes with strong hydrophobic character can bind prostaglandin fatty-acid moieties; first-filtrate assay loss is therefore measured during filter compatibility validation. If initial filtrate recovery falls below the release limit, the membrane is pre-saturated with a small volume of bulk solution that is discarded. Post-filtration filter integrity is tested by bubble point or diffusion flow before and after filling. Aseptic filling occurs in an ISO 14644-1 Class 5 environment using barrier isolator technology. Type I borosilicate glass vials of 10 mL, 30 mL, or 100 mL are filled, stoppered with chlorobutyl closures, and sealed with aluminum caps. Headspace oxygen is controlled by nitrogen flushing. Terminal product is a sterile multidose injection, 5 mg/mL dinoprost equivalents, for intramuscular administration in cattle.
| Species | Labeled dose as dinoprost | Volume at 5 mg/mL | Primary reference | Terminal finished form |
|---|---|---|---|---|
| Cattle | 25 mg | 5 mL | 21 CFR 522.690 | Sterile multidose injection |
| Swine | 10 mg | 2 mL | 21 CFR 522.690 | Sterile injectable solution |
| Equine | 5 mg | 1 mL | 21 CFR 522.690 | Sterile injectable solution |
For sow parturition induction, the labeled dose is 10 mg dinoprost, or 2 mL of 5 mg/mL solution, administered intramuscularly within 3 days before the expected farrowing date. The same 6.7 mg/mL dinoprost tromethamine salt input is used, but the formulation design differs from bovine multidose presentations because the pig farm administration environment places greater pressure on syringeability and cold-chain stability. Buffer selection is constrained by three factors: PGF₂α tromethamine is susceptible to alkaline hydrolysis, divalent cations present in water for injection can form carboxylate salts, and acetate or borate buffers may alter the charged state of the acidic prostaglandin moiety during terminal filtration. A tromethamine-stabilized system at pH 6.9–7.4 is therefore preferred over carbonate buffers. Published data for divalent cation tolerance at production scale is limited; therefore conductivity and calcium/magnesium ion limits must be set through site-specific process capability rather than compendial assumptions.
The regulatory path for this presentation is the swine indication under 21 CFR 522.690. The finished product is a parenteral solution, so the same sterility, endotoxin, particulate, and container-closure compendial tests apply: USP <71>, USP <85>, USP <788>, and USP <790>. Stability protocols follow VICH GL3 for climatic zones relevant to swine-producing regions; if the product is registered in the European Union, the marketing authorization dossier also includes a Ph. Eur. 5.1.1 sterility section and residual solvent data under VICH GL18. Preservative-free single-dose ampules are an option, but if a 100 mL multidose vial is filled for farrowing-house use, the antimicrobial preservative system is validated to USP <51>.
Manufacture follows the same cold dissolution and nitrogen-sparged sequence as the cattle product, but filling is configured for 10 mL and 100 mL presentations. The bulk solution is filtered through a 0.22 µm membrane, and the filter train is subjected to a pre-use integrity test because swine reproductive drugs are often filled as campaigns after a previous campaign without line breakage. If the line is not dedicated, cleaning validation must demonstrate removal of prostaglandin residues to the acceptance limit derived from carryover calculations. The aseptic filling line operates with restricted access barrier systems; fill-volume checks use gravimetric in-line dosing at ±0.2 mL tolerance for 10 mL vials. After filling, the vials are flushed with nitrogen to maintain headspace residual oxygen below the qualified limit. The final product is a sterile injectable solution for intramuscular farrowing induction in sows.
Equine cycle control formulations are constrained less by API solubility than by container-closure extractables under nitrogen-purged storage. For luteolysis in mares, the labeled dose is 5 mg dinoprost, delivered as 1 mL of 5 mg/mL solution. The active input is 6.7 mg/mL dinoprost tromethamine, corrected for potency. The finished presentation is frequently a 10 mL vial, and because equine reproductive clinical users may withdraw multiple doses over time, the stopper elastomer and headspace oxygen are critical stability variables. Chlorobutyl closures with low zinc and low sulfur content reduce prostaglandin degradation caused by extractable thiuram or zinc-salt residues. The formulation is adjusted to 260–330 mOsm/kg using sodium chloride, and the release pH is held within 6.8–7.4. The product must comply with 21 CFR 522.690 equine indications and the full parenteral compendial panel, including USP <788> subvisible particulate control for small-volume parenterals.
The production process mirrors the low-temperature, nitrogen-sparged aseptic route. API is dissolved at 20–25°C in water for injection, and the solution is passed through a 0.22 µm sterilizing-grade membrane. Because equine formulations may be packaged in 10 mL Type I glass vials with smaller neck sizes than bovine vials, filling speed is reduced to avoid splashing and excessive turbulence. The fill line is operated under ISO 14644-1 Class 5 conditions, and the stopper bowl is purged with nitrogen to minimize oxygen ingress. After filling, headspace oxygen is displaced with nitrogen and the product is stored at 2–8°C. Terminal product is a sterile injectable solution for intramuscular luteolysis in mares, with the 5 mg/mL label claim.
Terminal moist heat sterilization at 121°C is incompatible with aqueous PGF₂α tromethamine; the prostaglandin undergoes thermal and oxidative degradation that shifts assay below compendial acceptance limits. Sterile filtration at 0.22 µm is therefore the controlling unit operation. The formulation input remains 6.7 mg/mL dinoprost tromethamine equivalent to 5 mg/mL dinoprost, with tonicity maintained at 260–330 mOsm/kg. Because the process lacks a terminal kill step after filling, the manufacturing risk is shifted upstream to bioburden control, environmental monitoring, and filter integrity. This makes the aseptic filling operation the highest-variance step in the entire process. Production-scale failure modes include filter membrane plugging by trace peroxide degradation products, first-dose assay loss due to membrane adsorption, and particulate formation during temperature fluctuation in storage.
Validation of the filtration process is driven by 21 CFR 211.113(b); the filter is challenged with a documented minimum bacterial retention consistent with the membrane manufacturer’s use of Brevundimonas diminuta ATCC 19146 at 107 CFU/cm2. Sterility is verified by USP <71> or Ph. Eur. 2.6.1, endotoxin by USP <85> or Ph. Eur. 2.6.14, and subvisible particulates by USP <788>. The aseptic core is classified as ISO 14644-1 Class 5 at rest, with continuous viable and non-viable particle monitoring per ISO 14644-2. Process simulation media fills are required at initial qualification and re-qualification intervals, with target contamination rate below regulatory alert limits and no actionable recurrence.
At 500 L scale, the bulk solution is chilled to 20°C before filtration to reduce membrane resistance and to minimize the thermal degradation rate. A two-stage filter train is used: a 0.45 µm prefilter followed by two 0.22 µm sterilizing-grade membranes in series. The first 0.22 µm membrane protects the final sterilizing filter from upstream bioburden breakthrough; the second is located immediately before the filling needle. Pre-use integrity testing is conducted after steaming or sanitization, and post-use integrity testing is completed after filling. If the post-use integrity test fails, the entire batch is rejected. The fill line uses peristaltic or rotary piston pumps with minimal shear; the product is filled under laminar flow into Type I glass vials with nitrogen flushing before stoppering. The terminal product is a sterile multidose injectable solution for use in cattle, swine, or equine species as specified in the registered labeling. The completed batch is held in quarantine under 2–8°C until release testing confirms identity, assay, pH, osmolality, particulate matter, sterility, and endotoxin compliance.
Veterinary compounding from bulk dinoprost tromethamine presents a split between sterile injectable compounding and non-sterile oral capsule compounding. In sterile practice, the target concentration is 5 mg/mL dinoprost equivalent, prepared from 6.7 mg/mL dinoprost tromethamine in a sterile vehicle. This addition ratio is anchored to the approved injection label under 21 CFR 522.690 rather than to a separate oral dosage standard. Compounded sterile injections are prepared in an ISO 14644-1 Class 5 laminar airflow workbench; the API is dissolved in sterile water for injection or sterile saline at 20–25°C, passed through a 0.22 µm sterile filter, and aseptically transferred into amber Type I glass vials. The terminal product is a patient-specific sterile injectable solution for intramuscular use in cattle, swine, or equine patients when an approved product cannot be used. Non-sterile oral capsules and tablets cannot be assigned the same addition ratio because prostaglandin F₂α tromethamine undergoes significant first-pass metabolism; published data for oral veterinary capsules or tablets is limited. If a veterinarian directs an oral compounded form, the preparation must be labeled as a data-limited adaptation, and the dose cannot be extrapolated arithmetically from the intramuscular label.
Compliance for this downstream segment is governed by the national veterinary compounding framework; in the United States, compounding from bulk drug substances is not automatically legal and must comply with the conditions of 21 CFR 530 as applicable, including the list of bulk drug substances and office stock provisions. Both USP <797> for sterile compounding and USP <795> for nonsterile compounding are applied by many state boards of pharmacy. Endotoxin testing on the bulk API and the vehicle is necessary because extemporaneous compounding lacks terminal sterilization. The final sterile preparation is subject to a beyond-use date established by USP <797> risk categories for low-risk compounded sterile preparations, and the non-sterile oral product is assigned a beyond-use date under USP <795>. This scenario is included because the API powder physical form is used for extemporaneous preparation, but the oral and capsule configurations are subordinate to the injectable route in regulatory and clinical practice.
Competitive Trometamol Prostaglandin F₂α Injection Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Trometamol Prostaglandin F₂α Injection Veterinary Grade API, also designated as dinoprost tromethamine, is the 1:1 tromethamine salt of prostaglandin F₂α, identified by CAS 38562-01-5 and represented as C20H34O5·C4H11NO3. The product is a white to off-white crystalline powder intended for formulation into tablets, injections, capsules, powders, granules, premix, and solutions. The salt form is preferred where aqueous solubility and rapid dissolution are required, because prostaglandin F₂α free acid has limited water solubility under neutral pH conditions. The API is controlled for assay, related substances, residual solvents, water content, and bacterial endotoxins using pharmacopoeial methods applicable to prostaglandin F₂α or its tromethamine salt. Storage in tightly closed containers at 2–8 °C with protection from light is required; exposure to atmospheric moisture above 60% RH increases the risk of hygroscopic uptake and particle agglomeration.
Salt formation with trometamol produces a water-soluble species because the amino alcohol contains a primary amine that ionises with the carboxylic acid moiety of prostaglandin F₂α, while its hydroxyl groups increase hydrophilicity. The resulting salt dissolves rapidly in Water for Injection at ambient temperature; solution clarity is assessed after reconstitution by visual inspection according to Ph. Eur. 2.9.20 or equivalent. In contrast, the free acid requires organic co-solvents or pH adjustment to achieve comparable concentrations, which complicates aqueous injection manufacture. The trometamol salt also contributes buffering capacity; the finished solution is usually adjusted to pH 7.0–8.0 with hydrochloric acid or sodium hydroxide, because prostaglandin F₂α undergoes pH-dependent dehydration and epimerisation outside this window. Aqueous stability studies are conducted under ICH Q1A(R2) stress conditions at 40 °C/75% RH and 25 °C/60% RH to establish finished product shelf life; published data for the exact degradation rate constant of this specific veterinary-grade configuration is limited.
Release specification compliance includes identification by infrared absorption spectrophotometry according to USP <197> or Ph. Eur. 2.2.24, with the spectrum compared against a certified dinoprost tromethamine reference standard. Assay by liquid chromatography is conducted using octadecylsilyl silica columns with ultraviolet detection at 200–210 nm; the method is validated for specificity, linearity, accuracy, and precision according to ICH Q2(R1). Related substances are separated by gradient elution and reported on the dried basis. Water content by Karl Fischer titration according to USP <921> or Ph. Eur. 2.5.12 is controlled to maintain flowability and reduce hydrolytic degradation during solid dosage processing. Residual solvent levels are monitored under USP <467> or Ph. Eur. 5.4; ethanol, methanol, and acetone are the most frequently observed class 3 solvents in the final crystallisation path.
| Control parameter | Method / standard | Release acceptance basis |
|---|---|---|
| Identification | USP <197>, Ph. Eur. 2.2.24 | IR spectrum concordant with dinoprost tromethamine reference |
| Assay | USP <621>, Ph. Eur. 2.2.29 | 95.0–105.0% on dried basis |
| Related substances | USP <621> gradient HPLC | Total impurities ≤ 2.0%; individual impurities as authorised monograph |
| Water content | USP <921>, Ph. Eur. 2.5.12 | ≤ 1.0% for solid oral and premix grades |
| Residual solvents | USP <467>, Ph. Eur. 5.4 | Class 2 and class 3 limits per target-species risk assessment |
| Bacterial endotoxins | USP <85>, Ph. Eur. 2.6.14 | Calculated from dose and 5 EU/kg parenteral threshold |
| Particle size | USP <429>, Ph. Eur. 2.9.31 | D90 controlled to grade-dependent range |
For injection-grade material, the bacterial endotoxin limit is not a fixed universal value but is derived from the maximum intended veterinary dose and the parenteral threshold of 5 EU/kg body mass specified in USP <85> and Ph. Eur. 2.6.14. The calculation incorporates the maximum bolus dose per kilogram in the target species, the dosing interval, and the finished product concentration. Endotoxin testing by Limulus amebocyte lysate method is performed after reconstitution or dissolution using endotoxin-free water; inhibition or enhancement is controlled by positive product controls. The API itself is not represented as sterile; terminal sterilisation or aseptic filtration of the finished injection remains mandatory. Pre-filtration bioburden is maintained below 10 CFU/100 mL for sterilising-grade filtration according to ISO 13408-1 and current good manufacturing practice expectations, although published data for this specific API in production-scale filtration is limited. Particulate matter in the finished injection is controlled according to USP <788> or Ph. Eur. 2.9.19, with limits for sub-visible particles of ≥10 µm and ≥25 µm applied to the final container.
Accelerated degradation of prostaglandin F₂α in aqueous solution typically follows apparent first-order kinetics, but the observed rate constant depends on buffer species, ionic strength, oxygen headspace, and light exposure. The 15-hydroxyl group is particularly sensitive to epimerisation, while the 5,6- and 13,14-double bonds are subject to oxidative cleavage. Nitrogen overlay reduces oxidative pathways but does not eliminate pH-dependent dehydration. Therefore, pH drift is monitored during long-term stability; a shift greater than 0.5 pH units from the release value triggers review under the finished product stability protocol. Polytetrafluoroethylene and polyvinylidene fluoride membranes are commonly evaluated for sterilising-grade filtration; polyamide membranes may be avoided because of potential binding of the prostaglandin carboxyl group. Filter bubble-point and diffusion tests are performed before and after filtration according to ISO 13408-2 or manufacturer recommendations. The filtration process is validated with a worst-case challenge using Brevundimonas diminuta at a concentration of at least 10⁷ CFU/cm² membrane area.
Direct compression and dry granulation are preferred over wet granulation when the API is formulated into tablets or capsules because aqueous granulation introduces moisture that can accelerate hydrolysis and epimerisation. The API is milled to a particle size distribution with D90 controlled to a grade-dependent range, typically below 250 µm, to support content uniformity in low-dose blends; particle size is determined by laser diffraction according to USP <429> or Ph. Eur. 2.9.31. For tablets containing 5 mg or less of dinoprost equivalent per unit, a geometric dilution sequence with a directly compressible filler such as microcrystalline cellulose and anhydrous dibasic calcium phosphate is used. Content uniformity is evaluated according to USP <905> or Ph. Eur. 2.9.40; acceptance values are calculated from the first 10 dosage units. Lubrication with magnesium stearate is limited to 1.0% w/w and mixing time is controlled because the hydrophobic lubricant can reduce tablet tensile strength and delay dissolution. The API is incompatible with strongly alkaline excipients, reducing sugars, and primary amine-containing binders that promote Maillard-type reactions or salt disproportionation. Dissolution testing, where required, follows USP <711> with a pH 6.8 phosphate buffer medium; published data for the specific dissolution profile of this veterinary grade in solid oral matrices is limited.
Encapsulation of the API into hard gelatin or hydroxypropyl methylcellulose capsules is performed under controlled low-humidity conditions, typically 20–30% RH, because the trometamol salt is hygroscopic and can soften capsule shells if moisture is excessive. For powders and granules, the API is preblended with a portion of carrier by geometric dilution before being passed through a sieve of 500 µm to break agglomerates. The blend is then mixed in a low-shear tumble blender; fill weight and content uniformity are verified after discharge from at least 10 sampling locations. Granules for veterinary oral solutions or feed incorporation are manufactured by dry granulation or fluid-bed granulation using anhydrous binders; water-based binders are avoided unless the drying step can reduce water activity below 0.6 at the granule surface. Published data for the specific stability of this API in flavoured oral powders for companion animals is limited; accelerated stability is therefore required for each finished formulation.
Manufacture of aqueous injection solutions begins with dissolution of the API in Water for Injection at 15–25 °C; the trometamol salt dissolves without organic co-solvents. The solution is sparged with nitrogen because prostaglandin F₂α is susceptible to oxidative degradation; sodium metabisulfite or other antioxidants may be added if justified by compatibility data. The pH is measured with a calibrated potentiometric electrode and adjusted to 7.0–8.0 using dilute hydrochloric acid or sodium hydroxide. The bulk solution is filtered through a 0.22 µm sterilising-grade membrane; compatibility of the membrane and filter housing with the solution is confirmed by filter validation. Terminal steam sterilisation may be used for heat-stable container systems, but many manufacturers select aseptic filtration because prostaglandin F₂α can degrade at prolonged sterilisation temperatures. Filled vials are purged with nitrogen and sealed with halogenobutyl rubber closures; light-protective secondary packaging is required to prevent photoisomerisation of the 13E double bond. In-use stability after first broaching is evaluated for the maximum intended dosing period and is part of the finished product authorisation.
The trometamol salt of prostaglandin F₂α retains the native C20 prostanoic acid backbone and therefore requires higher mass doses in cattle than synthetic analogues such as cloprostenol sodium and alfaprostol. Cloprostenol contains a 16-(3-chlorophenoxy) modification that increases luteolytic potency and prolongs the effective half-life in cattle; the labelled dose of cloprostenol sodium is lower than that of dinoprost tromethamine for luteolysis and estrus synchronisation in the same species. This product is differentiated from those analogues by its closer structural identity to endogenous PGF₂α, which can be relevant when species-specific receptor binding is considered. In swine, dinoprost tromethamine is used for induction of parturition within a defined gestational window; the response depends on the stage of corpus luteum maturity and is not equivalent to oxytocin-induced labour. In equine practice, the API is used for luteolysis in mares; transient sweating, tachycardia, and abdominal discomfort are recognised species-specific adverse effects. Published data for direct comparative receptor binding affinity of this specific veterinary-grade salt is limited; formulation and dosing decisions should therefore be based on the authorised finished product label rather than on in vitro potency extrapolation.
Residual solvent control follows USP <467> and Ph. Eur. 5.4; class 1 solvents such as benzene and carbon tetrachloride are limited to pharmacopoeial thresholds or are excluded by the manufacturing route. Class 2 solvents such as dichloromethane and methanol are quantified by headspace gas chromatography with flame ionisation detection; acceptance limits are based on the permitted daily exposure for the target species, not on human parenteral limits alone. Elemental impurities are controlled according to USP <232>/USP <233> or ICH Q3D; the veterinary risk assessment considers oral and parenteral routes, body mass variability, and the longer production lifespans of food-producing animals. In premix and granule operations, the API is typically dispersed on lactose monohydrate, dextrose, or calcium carbonate carriers; lactose-based premixes require moisture control below 0.5% loss on drying to prevent caking and uneven distribution. Homogeneity testing is performed according to ISO 6497 or regional feed sampling standards using at least 10 incremental samples per batch; published data for the specific carryover and homogeneity of this API in medicated feed premixes is limited.
Because the API is active at microgram-to-milligram doses in some species, cross-contamination control during tablet, capsule, premix, and granule manufacture requires dedicated or validated cleaning procedures. Cleaning validation is performed according to risk-based limits derived from the acceptable daily exposure and the next product batch size; analytical methods for swab and rinse samples are validated under ICH Q2(R1). Weighing and dispensing of the pure API are conducted in containment booths or isolators to control occupational exposure and prevent airborne dispersal into adjacent process suites. Production equipment with rough internal surfaces or dead legs should be avoided because the low-dose API can be retained in crevices and cause subsequent batch contamination.
Bulk API packaging is selected to limit moisture ingress and light exposure. Double polyethylene liners inside a fibre drum or aluminium-laminated bag are typical; desiccant is added when the product is shipped to humid climates. Oxygen-impermeable packaging is preferred for long-term storage because the 5,6- and 13,14-double bonds in the prostanoic acid chain are susceptible to autoxidation. Stability data are generated under ICH Q1A(R2) conditions at 25 °C/60% RH and 40 °C/75% RH; re-test periods are assigned from the resulting trend analysis. Storage outside the labelled 2–8 °C range for extended periods cannot be compensated by later refrigeration and may result in increased related substances. For a specific production campaign, the API should be warmed to ambient temperature inside the sealed container before opening to prevent condensation on the powder surface.
The API is incompatible with strongly acidic or strongly basic conditions. At pH below 4.0, the prostanoic acid moiety may protonate and reduce aqueous solubility; at pH above 9.0, base-catalysed dehydration and epimerisation of the 15-hydroxyl group are accelerated. The API should not be blended with alkali metal hydroxides, ammonia-generating excipients, or aluminium-magnesium silicate carriers that can raise the microenvironmental pH. In aqueous injection solutions, Type I borosilicate glass containers according to USP <660> or Ph. Eur. 3.2.1 are used for finished injections. Rubber closures should be selected to minimise sorption of the active substance.
During milling and blending, process analytical technology may be applied to monitor blend uniformity in real time. A near-infrared calibration set should include at least 3 API concentration levels spanning 70–130% of target and a minimum of 20 samples per level to meet method validation expectations under ICH Q2(R1). Air-jet milling may produce localised heating; mill outlet temperature is monitored and maintained below 40 °C to reduce the risk of dehydration or isomerisation. Particle size distribution is recorded as D10/D50/D90 for each lot because batch-to-batch variability can affect dissolution rate in tablets and uniformity in low-dose premixes.
